logo
AM Best Assigns Credit Ratings to China United Property Insurance Company

AM Best Assigns Credit Ratings to China United Property Insurance Company

Business Wire4 days ago
HONG KONG--(BUSINESS WIRE)-- AM Best has assigned a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of 'a' (Excellent) to China United Property Insurance Company (CUPI) (China). The outlook assigned to these Credit Ratings (ratings) is stable.
The ratings reflect CUPI's balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, favourable business profile and appropriate enterprise risk management. The ratings also reflect the expected government support CUPI will receive from its ultimate parent, China Investment Corporation (CIC), the sovereign wealth fund of the Chinese government.
CUPI's very strong balance sheet strength assessment is underpinned by its very strong level of risk-adjusted capitalisation, as measured by Best's Capital Adequacy Ratio (BCAR), which is projected to remain at a similar while declining level over the short to intermediate term. The company maintains a sizeable capital and surplus of RMB 18.5 billion (USD 2.53 billion) as of year-end 2024 based on AM Best calculation. The company's comprehensive solvency ratio under C-ROSS Phase II was significantly improved and its financial flexibility was enhanced following the successful issuance of a RMB 6 billion capital supplementary bond in late 2024, while the financial leverage remained at a neutral level. CUPI's investment portfolio is diversified, primarily consisting of bonds (including bond funds), cash and deposits, as well as listed equities. The company has moderate exposure in the real estate sector and a controlled growth into riskier investment types. Offsetting factors include its relatively high underwriting leverage compared to domestic peers of similar size, its large outstanding premium receivables on its balance sheets predominantly due to policy-driven agriculture insurance business and its exposure to impairments of some legacy investment.
CUPI has remained profitable over the last five years, delivering an annual return on equity in the mid-single-digit range. While the company historically maintains a slightly higher-than-industry growth, which is driven by its non-motor lines of business, CUPI expects its future top-line growth to be largely in line with the industry. The company's profit was mainly supported by investment income, while its underwriting results were around breakeven. Its investment yield ranged in the low to mid-single-digit range over the last few years, exhibiting some volatility due to capital market conditions. Nonetheless, AM Best expects CUPI to continue delivering positive investment income to support its overall profitability. Overall, CUPI's operating performance is assessed as adequate.
CUPI's favorable business profile is supported by its strong government connection, leading position in domestic agriculture insurance, diversified product offering and extensive distributional network. Incorporated in 1986, CUPI is the fifth largest non-life insurer in mainland China, with a market share of around 4% based on 2024 direct premium written. With a long operating history, CUPI has built strong underwriting know-how and customer servicing capabilities. Coupled with its strong ties across government levels, the company continues to maintain a leading position in policy-driven agriculture and short-term health insurance, which accounted for over 30% of its gross premium written in 2024. CUPI maintains a 12% market share in China's agriculture insurance market, which has become one of the largest agriculture insurance markets globally.
The ratings also recognise the strategic importance of CUPI in providing nationwide inclusive agriculture insurance and support to the country's national strategies. AM Best believes there is a high likelihood that CIC will provide support to CUPI, if needed. CIC is equipped with sound credit fundamentals and abundant financial resources. AM Best expects CUPI to further benefit from CIC's implicit support, including operational, risk management, and corporate governance.
Negative rating actions could occur if CUPI's balance sheet strength were to weaken significantly. A sustained deteriorating trend in underwriting and operating performance also may result in negative rating actions. Although unlikely in the short to intermediate term, positive rating actions could occur if the company demonstrates sustained improvement in balance sheet strength, via non-debt issuance source.
Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication.
This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Zydus Lifesciences gets USFDA final approval for Diltiazem Hydrochloride tablets
Zydus Lifesciences gets USFDA final approval for Diltiazem Hydrochloride tablets

Business Upturn

time9 minutes ago

  • Business Upturn

Zydus Lifesciences gets USFDA final approval for Diltiazem Hydrochloride tablets

By Aman Shukla Published on August 11, 2025, 10:10 IST Zydus Lifesciences Limited, along with its subsidiaries and affiliates (collectively referred to as 'Zydus'), has secured final approval from the United States Food and Drug Administration (USFDA) for its Diltiazem Hydrochloride Tablets USP in multiple strengths: 30 mg, 60 mg, 90 mg, and 120 mg. These tablets will be marketed under the brand name Cardizem® Tablets in the US. Diltiazem Hydrochloride Tablets are widely prescribed for managing chronic stable angina and angina caused by coronary artery spasms. Classified as calcium-channel blockers, these tablets work by relaxing blood vessels, thereby reducing the heart's workload and improving blood and oxygen flow to the heart muscle. This approval allows Zydus to manufacture the drug at its state-of-the-art facility in Baddi, Himachal Pradesh. According to IQVIA MAT data from June 2025, Diltiazem Hydrochloride Tablets generated annual sales of USD 13.9 million in the United States, highlighting the product's strong market demand. With this recent approval, Zydus has achieved a total of 423 USFDA approvals and has filed 483 ANDAs (Abbreviated New Drug Applications) since it began filing in the fiscal year 2003-04. This milestone underscores Zydus' commitment to expanding its footprint in the competitive US pharmaceutical market. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

Mini Diamonds shares jump on securing Rs 18.29 crore export order from Hong Kong client
Mini Diamonds shares jump on securing Rs 18.29 crore export order from Hong Kong client

Business Upturn

timean hour ago

  • Business Upturn

Mini Diamonds shares jump on securing Rs 18.29 crore export order from Hong Kong client

By Aditya Bhagchandani Published on August 11, 2025, 09:49 IST Shares of Mini Diamonds (India) Ltd rose on Monday after the company announced securing an export order worth USD 21,50,000 (approximately Rs 18.29 crore) for lab-grown cut and polished diamonds from a prominent Hong Kong–based client. The order, placed on August 11, 2025, will be executed within three months, with payment scheduled within 150 days. The company said this marks its entry into the Hong Kong market, a global hub for diamond trading, strengthening its presence in the Far East. Mini Diamonds' Chairman and Managing Director, Upendra N. Shah, said the order highlights growing international confidence in the company's quality and aligns with its long-term strategy to expand exports and diversify its customer base. Mini Diamonds manufactures diamonds and jewellery at its Mumbai facility, equipped with advanced technology such as Sarin machines, auto bruiting systems, and semi-automatic polishing mills. The deal was awarded by Jewellery Trendz Ltd, with delivery expected within the stipulated three-month period. The company expects the order to boost export revenues and open new opportunities in the Far East jewellery market. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

Rupee to rise at open on NDF lift; U.S. tariffs, inflation on radar
Rupee to rise at open on NDF lift; U.S. tariffs, inflation on radar

Yahoo

time2 hours ago

  • Yahoo

Rupee to rise at open on NDF lift; U.S. tariffs, inflation on radar

By Nimesh Vora MUMBAI (Reuters) -The rupee is set to open higher on Monday, supported by its recovery in the non-deliverable forward market, while traders remain focused on potential fallout from U.S. tariffs and the upcoming U.S. inflation data. The 1-month non-deliverable forward indicated the rupee will open in the 87.52-87.56 range versus the U.S. dollar, compared with 87.66 on Friday. The NDF move feels "purely positional" and there was no real shift in underlying sentiment, a currency trader at a Mumbai-based bank said, with the structural bias on USD/INR remaining higher till the tariff overhang is in play. The tactical adjustment in NDF likely reflects some trimming of heavy-dollar positions, with the Reserve Bank of India's intervention likely prompting speculators who were betting on a quick leg higher in USD/INR to think twice, the trader said. Over the last two weeks, the RBI has intervened in the non-deliverable forward and onshore spot markets to cushion the rupee against tariff pressures stemming from U.S. President Donald Trump's actions. SOFT US DOLLAR A broadly softer dollar, on growing bets of a Federal Reserve rate cut next month, is expected to aid the rupee amid the tariff noise. The dollar index fell on Monday, extending losses from last week, while most Asian currencies advanced. July U.S. inflation data, due on Tuesday, will be key to gauging Fed rate-cut expectations and the dollar's direction. While the full impact of the latest tariffs may take time to filter into the inflation numbers, the July print will still be heavily scrutinised, MUFG Bank said in a note, adding that June data already showed signs that tariff rates are starting to have a bigger impact. Traders currently see a 90% chance of a September Fed rate cut and are pricing in just over two cuts for the year. KEY INDICATORS: ** One-month non-deliverable rupee forward at 87.66; onshore one-month forward premium at 12 paise ** Dollar index down at 98.08 ** Brent crude futures down 0.5% at $66.3 per barrel ** Ten-year U.S. note yield at 4.28% ** As per NSDL data, foreign investors sold a net $629.4 million worth of Indian shares on Aug 7 ** NSDL data shows foreign investors bought a net $69.1 million worth of Indian bonds on Aug 7 Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store